Differences in lifetime risk of CRC are known, showing that carriers of pathogenic variants in MSH6 and PMS2 have a lower risk of developing cancer, especially CRC and at later ages of onset than those with variants in MLH1 and MSH24–12. This evidence concerns the gene PMS2 and colorectal carcinoma.